Trial Profile

An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glatiramer acetate (Primary)
Indications Multiple sclerosis
Focus Adverse reactions; Registrational
Acronyms Song
Sponsors Teva Pharmaceutical Industries

Most Recent Events

13 Oct 2010 Results presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
08 Jun 2010 Results were presented at the 24th Annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC), according to a Teva Pharmaceuticals media release.
03 May 2010 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com